The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Seliverstov E.I.

Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia

Andriiashkin V.V.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Leont'ev S.G.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Kirienko A.I.

Russian National Research Medical University nabbed after N.I. Pirogov, Moscow, Russia

Biosimilars analogs of enoxaparin: to what extent is their prescription justified for the treatment of venous thrombosis and pulmonary thromboembolism?

Authors:

Seliverstov E.I., Andriiashkin V.V., Leont'ev S.G., Kirienko A.I.

More about the authors

Journal: Journal of Venous Disorders. 2013;7(4): 57‑64

Read: 1239 times

Download PDF (RU)
Contact the author
Table of contents

BIOSIMILARS ANALOGS OF ENOXAPARIN: TO WHAT EXTENT IS THEIR PRESCRIPTION JUSTIFIED FOR THE TREATMENT OF VENOUS THROMBOSIS AND PULMONARY THROMBOEMBOLISM?
BIOSIMILARS ANALOGS OF ENOXAPARIN: TO WHAT EXTENT IS THEIR PRESCRIPTION JUSTIFIED FOR THE TREATMENT OF VENOUS THROMBOSIS AND PULMONARY THROMBOEMBOLISM?

To cite this article:

Seliverstov EI, Andriiashkin VV, Leont'ev SG, Kirienko AI. Biosimilars analogs of enoxaparin: to what extent is their prescription justified for the treatment of venous thrombosis and pulmonary thromboembolism? Journal of Venous Disorders. 2013;7(4):57‑64. (In Russ.)

Подписка 2026 Флебология (Journal of Venous Disorders)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Posi­tive Predictive Value of the Wells Score in Diagnosis of Deep Vein Thro­mbosis: Resu­lts of Bayesian Analysis. Journal of Venous Diso­rders. 2024;(4):274-282
Asplenia — a new cause of thro­mbosis in pregnant women?. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):71-76
Hemo­stasis diso­rders during neoadjuvant therapy in patients with breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(3):39-44
Effi­cacy and Safety of the Oral Anti­coagulant DIMO­LEGIN Compared to Enoxaparin Sodium for the Prevention of Venous Thro­mboembolism Following Major Joint Replacement Surgery (hip or knee arthroplasty): A Randomized, Double-Blind, Multicenter Trial. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):577-585
Abstract:

Venous thromboembolism is a challenging problem in modern medicine. Low-molecular weight heparins are the medicines most extensively employed to prevent and treat venous thrombosis and thromboembolism; their effectiveness and safety are fairly well confirmed in multicenter randomized clinical studies. At present, the patent protection of many of these agents including fractionated heparins is about to be lost. It motivated certain pharmaceutical companies to start manufacture of generic low-molecular weight heparins. However, the original formulations and generic medications possess different anticoagulation activity despite their similar structure, physical and chemical properties. That is why, the results of investigations of the original medications can not be extrapolated to their biological analogs. The effectiveness and safety of each generic low-molecular weight heparin need to be confirmed in special clinical studies. The leading world pharmacovigilance organizations adhere to this principle.

Keywords:

venous thromboembolism
low-molecular weight heparins
generics
biological analogs

Authors:

Seliverstov E.I.

Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia

Andriiashkin V.V.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Leont'ev S.G.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Kirienko A.I.

Russian National Research Medical University nabbed after N.I. Pirogov, Moscow, Russia

Close metadata

References:

  1. Khasabov N.N., Zemskova N.A. Biologicheskie lekarstvennye sredstva i ikh bioanalogi: opredelenie, voprosy kachestva, identichnosti i bezopasnosti [Biological medicines and their biological analogs: the definition problems of quality, identity, and safety]. Vestnik Roszdravnadzora 2008; 6: 34-38.
  2. International Trade Administration. PharmaceuticalIndustryProfile2010 http://ita.doc.gov/td/health/PharmaceuticalIndustryProfile2010.pdf. Доступно 11.06.13
  3. Биоаналоги низкомолекулярных гепаринов: сходство в обмен на эффективность? Клин фармакол и терап 2012; 21: 3: 5-11.  Bioanalogi nizkomolekulyarnykh geparinov: skhodstvo v obmen na effektivnost'? Klin farmakol i terap 2012; 21: 3: 5-11.
  4. Zyryanov K.S., Belousov Yu.B. Original'nye i vosproizvedennye biologicheskie lekarstvennye sredstva: otsenka ekvivalentnosti [Original and reproduced biological medicines: the assessment of equivalence]. Upravlenie zdravookhr 2012; 1: 32.
  5. Walenga J.M., Hoppensteadt D., Cunanan J. et al. Immunogenicity of low molecular weight heparins and their biosimilars. 3rd Workshop on the characterization of heparin products. USP Headquarters: Rockville Maryland (USA) 2009.
  6. Fareed J., Hoppensteadt D., Schulz C. Biochemical and pharmacological heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Curr Pharm Des 2004; 10: 983-999.
  7. Nugent M. Heparin sequencing brings structure to the function of complex oligosaccharides. Proc Natl Acad Sci USA 2000; 97: 19: 10301-10303.
  8. Turnbull J., Powell A. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Cell Biol 2001; 11: 2: 75-82.
  9. Hirsh J. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 134: 2: 473.
  10. Casu B., Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 2001; 57: 159-206.
  11. Casu B., Torri G. Structural characterization of low molecular weight heparins. Semin Thromb Hemost 1999; 25: Suppl 3: 17-25.
  12. Lima M.A., Eduardo H.C. de Farias. Structural and Pharmacological Profile of Generic Enoxaparins Used in Brazil. Clin Appl Thromb Hemost 2012; 18: 4: 379-386.
  13. Walenga J., Jeske W., Hoppensteadt D., Cunanan J., Khan H., Escalante V., Fareed J. Comparative Studies on Branded Enoxaparin and a US Generic Version of Enoxaparin. Clin Appl Thromb Hemost 2013; 19: 3: 261-267.
  14. Fareed J., Bick R. The immunogenic potential of generic version of low-molecular-weight heparins may not be the same as the branded products. Clin Appl Thromb Hemost 2008; 14: 1: 5-7.
  15. FDA US Food and Drug Administration. Establishing Active Ingridient Sameness For A Generic Enoxaparin Sodium a Low Molecular Weight Heparin. Internet available at http://www.fda.gov/drugs/drug safety/postmarket drug safety information for patient sandproviders/ucm220023.htm
  16. Pinto V.F. Non-inferiority equivalence clinical trials in assessing biological products. San Paolo Med J 2011; 129: 183-184.
  17. European Medicine Agency. Committee for Medical Products for Human Use. Guideline on non-clinical and clinical development of biological medicinal products containing low-molecular-weight-heparins. Internet. Available at http://www.emea.europa.eu/docs/en_GB/document_library/scientific_guideline/2009/09/WC500003927.pdf
  18. Harenberg J., Kakkar A., Bergqvist D., Barrowcliffe T., Casu B., Fareed J., Mismetti P., Ofosu F.A., Raake W., Samama M., Schulman S. Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost 2009; 7: 7: 1222-1225.
  19. World Health Organization. Guidelines on evaluation of similar biotheraupeutic products.2009. http://who.int/biologicals/areas/biological_therapeutics/biotherapeutics_for_web_22april2010.pdf2
  20. Harenberg J., Walenga J., Torri G., Dahl O., Drouet L., Fareed J. The Subcommittee on Control of Anticoagulation of the Scientific Standardization Committee of the International Society on Thrombosis Haemostasis.Update of the Recommendations on Biosimilar Low-Molecular-Weight Heparins from the Scientific Subcommittee on Control of Anticoagulation of the ISTH. J Thromb Haemost 2013.
  21. Zyryanov S.K. Zaklyuchenie nauchnoy sessii VNOK: Lekarstvennye sredstva biologicheskogo proiskhozhdeniya i ikh analogi [Resolution of the scientific session of the All-Russian Scientific Society of Cardiologists. Medications of biological origin and their analogs]. Ros kardiol zhurn 2012; 2: 94: 15-16.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.